亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus

作者
Yanyu Lin,Shuen-Fu Weng,Chung-Huei Hsu,Chen-Ling Huang,Yu-Pei Lin,Min-Chun Yeh,A-Young Han,Yu-Shan Hsieh
出处
期刊:Frontiers in Medicine [Frontiers Media]
卷期号:9: 995944-995944 被引量:15
标识
DOI:10.3389/fmed.2022.995944
摘要

Background In this study, we aimed to compare the effects of metformin-based dual therapy versus triple therapy on glycemic control and lipid profile changes in Taiwanese patients with type 2 diabetes mellitus (T2DM). Methods In total, 60 patients were eligible for participation in this study. Patients received at least 24 months of metformin monotherapy, dual therapy, or triple therapy with metformin plus linagliptin (a dipeptidyl peptidase 4 (DPP-4) inhibitor) or dapagliflozin (a sodium-glucose cotransporter-2 (SGLT2) inhibitor). Blood samples were collected from each patient, followed by evaluation of changes in their blood glucose control and lipid profile-related markers. Results A combination of metformin and DPP4 and SGLT2 inhibitor therapy more effectively reduced low-density lipoprotein cholesterol (LDL-C) ( p = 0.016) than metformin monotherapy. A combination of metformin and DPP4 and SGLT2 inhibitor therapy more effectively improved total cholesterol (Chol, p = 0.049) and high-density lipoprotein cholesterol (HDL-C) than metformin monotherapy ( p = 0.037). Metformin plus linagliptin dual therapy was more effective than metformin monotherapy in reducing glycosylated hemoglobin (HbA1C, p = 0.011). Patients who received a combination of linagliptin and empagliflozin showed a significant reduction in their fasting blood glucose ( p = 0.019), HbA1c ( p = 0.036), and Chol ( p = 0.010) compared with those who received linagliptin dual therapy. Furthermore, patients who received metformin plus dapagliflozin and saxagliptin showed significantly reduced Chol ( p = 0.011) and LDL-C ( p = 0.035) levels compared with those who received metformin plus dapagliflozin. Conclusion In conclusion, dual therapy with metformin and linagliptin yields similar glycemic control ability to triple therapy. Among metformin combination triple therapy, triple therapy of empagliflozin and linagliptin might have a better glycemic control ability than dual therapy of linagliptin. Moreover, Triple therapy of dapagliflozin and saxagliptin might have a better lipid control ability than dual therapy of dapagliflozin.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dnpl完成签到,获得积分10
2秒前
5秒前
温婉的安彤完成签到,获得积分10
13秒前
SEN关注了科研通微信公众号
13秒前
自觉的猕猴桃完成签到,获得积分10
26秒前
Orange的应助被糊涂的初柔采纳,获得10
28秒前
28秒前
酷酷云朵完成签到,获得积分10
28秒前
30秒前
369ninja的应助被科研通管家采纳,获得10
31秒前
奔跑的应助被科研通管家采纳,获得10
31秒前
奔跑的应助被科研通管家采纳,获得10
31秒前
SEN发布了新的文献求助10
36秒前
47秒前
默默无闻完成签到 ,获得积分10
49秒前
小小昌发布了新的文献求助10
52秒前
52秒前
59秒前
1分钟前
1分钟前
现代的如容完成签到,获得积分10
1分钟前
彭于晏的应助被小小昌采纳,获得10
1分钟前
1分钟前
1分钟前
怕孤单的雪瑶完成签到,获得积分10
1分钟前
快乐的雁露完成签到,获得积分10
1分钟前
1分钟前
高挑的语蓉完成签到,获得积分10
1分钟前
1分钟前
回家放羊完成签到 ,获得积分10
1分钟前
曾经凌萱发布了新的文献求助10
1分钟前
科研通AI6.3的应助被曾经凌萱采纳,获得10
1分钟前
林夕完成签到,获得积分10
2分钟前
2分钟前
酷波er的应助被可爱的白猫采纳,获得10
2分钟前
2分钟前
哭泣振家完成签到,获得积分10
2分钟前
2分钟前
2分钟前
安静风华完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179877
求助须知:如何正确求助?哪些是违规求助? 9570060
关于积分的说明 21808221
捐赠科研通 7775626
什么是DOI,文献DOI怎么找? 3433171
关于科研通互助平台的介绍 2557308
邀请新用户注册赠送积分活动 2478846